Autocrine Fibronectin Inhibits Breast Cancer Metastasis


Journal article


Aparna Shinde, Sarah Libring, Aktan Alpsoy, A. Abdullah, J. A. Schaber, Luis Solorio, Michael K. Wendt
Molecular Cancer Research, 2018

Semantic Scholar DOI PubMed
Cite

Cite

APA   Click to copy
Shinde, A., Libring, S., Alpsoy, A., Abdullah, A., Schaber, J. A., Solorio, L., & Wendt, M. K. (2018). Autocrine Fibronectin Inhibits Breast Cancer Metastasis. Molecular Cancer Research.


Chicago/Turabian   Click to copy
Shinde, Aparna, Sarah Libring, Aktan Alpsoy, A. Abdullah, J. A. Schaber, Luis Solorio, and Michael K. Wendt. “Autocrine Fibronectin Inhibits Breast Cancer Metastasis.” Molecular Cancer Research (2018).


MLA   Click to copy
Shinde, Aparna, et al. “Autocrine Fibronectin Inhibits Breast Cancer Metastasis.” Molecular Cancer Research, 2018.


BibTeX   Click to copy

@article{aparna2018a,
  title = {Autocrine Fibronectin Inhibits Breast Cancer Metastasis},
  year = {2018},
  journal = {Molecular Cancer Research},
  author = {Shinde, Aparna and Libring, Sarah and Alpsoy, Aktan and Abdullah, A. and Schaber, J. A. and Solorio, Luis and Wendt, Michael K.}
}

Abstract

Both epithelial–mesenchymal transition (EMT) and mesenchymal–epithelial transition (MET) are linked to metastasis via their ability to increase invasiveness and enhance tumor-initiating capacity. Growth factors, cytokines, and chemotherapies present in the tumor microenvironment (TME) are capable of inducing EMT, but the role of the extracellular matrix (ECM) in this process remains poorly understood. Here, a novel tessellated three-dimensional (3D) polymer scaffolding is used to produce a fibrillar fibronectin matrix that induces an EMT-like event that includes phosphorylation of STAT3 and requires expression of β1 integrin. Consistent with these findings, analysis of the METABRIC dataset strongly links high-level fibronectin (FN) expression to decreased patient survival. In contrast, in vitro analysis of the MCF-10A progression series indicated that intracellular FN expression was associated with nonmetastatic cells. Therefore, differential bioluminescent imaging was used to track the metastasis of isogenic epithelial and mesenchymal cells within heterogeneous tumors. Interestingly, mesenchymal tumor cells do not produce a FN matrix and cannot complete the metastatic process, even when grown within a tumor containing epithelial cells. However, mesenchymal tumor cells form FN-containing cellular fibrils capable of supporting the growth and migration of metastatic-competent tumor cells. Importantly, depletion of FN allows mesenchymal tumor cells to regain epithelial characteristics and initiate in vivo tumor growth within a metastatic microenvironment. Implications: In contrast to the tumor-promoting functions of fibronectin within the ECM, these data suggest that autocrine fibronectin production inhibits the metastatic potential of mesenchymal tumor cells. Mol Cancer Res; 16(10); 1579–89. ©2018 AACR.


Tools
Translate to